| Document |
Document Title |
|
WO/2018/167687A1 |
Disclosed herein are compounds for use in lightening skin, treating uneven skin pigmentation and/or improving the appearance of aging skin, as well as methods utilizing the compounds, and anti-aging compositions comprising the compounds ...
|
|
WO/2018/169055A1 |
It is known that foods containing a carbohydrate, e.g., starch, in a large amount generate acrylamide upon heating at high temperatures. Some documents state that acrylamide is formed by the Maillard reaction of an amino acid, e.g., aspa...
|
|
WO/2018/169063A1 |
Provided is a novel technique for treating cancer using structurally-reinforced S-TuD. Provided are: a composition for the prevention or treatment of tumors, said composition comprising an miRNA inhibitory complex including RNA of analog...
|
|
WO/2018/165112A1 |
The present invention relates to a compound represented by formula (I), a method for the preparation thereof, and a pharmaceutical composition containing the compound as an active ingredient for inhibiting histone methyltransferase such ...
|
|
WO/2018/161938A1 |
A gynecological vaginal wash for adjusting female vaginal microecology and a preparation method thereof. The wash is prepared by adding a natural fragrance to acidic water with an acidic water volume concentration of 0.01-0.5% and adjust...
|
|
WO/2018/157750A1 |
Disclosed in the present invention are applications of rifamycin-nitroimidazole coupling molecules represented in formula (I) of the present invention in restraining anaerobic floras. The rifamycin-nitroimidazole coupling molecules repre...
|
|
WO/2018/160335A1 |
The embodiments include methods of improving sexual function in a male with benign prostatic hyperplasia (BPH), using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method include...
|
|
WO/2018/159632A1 |
[Problem] To provide a material for improving endometriosis with which it is possible to improve endometriosis and which is a material in which aglycone isoflavones are utilized, and a method for producing the material. [Solution] Produc...
|
|
WO/2018/160158A1 |
The present invention relates to compositions, particularly compositions useful in maintaining and supporting healthy microflora in the female urogenital tract which could lead to inhibition of vaginal infections, as well as methods of t...
|
|
WO/2018/156960A1 |
The invention provides safe and efficacious treatments for the improvement of male and female sexual function, cutaneous inflammation such as psoriasis, eczema, dermatitis and Female Sexual Disorders, such as Genitopelvic Pain/Penetratio...
|
|
WO/2018/153297A1 |
The present invention provides a novel ligand for the dopamine D3 receptor and a preparation method therefor. The compound, and a pharmaceutically acceptable salt and a pharmaceutical combination or a pharmaceutical preparation thereof a...
|
|
WO/2018/152001A1 |
The invention provides methods for analyzing a patient's potential for achieving ongoing pregnancy with respect to a specific fertility treatment. These methods involve conducting one or more tests on the patient to determine a body mass...
|
|
WO/2018/146332A1 |
The invention relates to the novel medical indication for the use of Lactobacillus buchneri for increasing the fertility of a female mammal by intra-uterine application of the Lactobacillus buchneri, the mammal having sub-clinical endome...
|
|
WO/2018/146689A1 |
The present invention is directed to methods and uses of a series of compounds and compositions comprising the same for treating diseases, disorders and/or conditions related to fertility and preserving same and conditions related to sam...
|
|
WO/2018/139679A1 |
Disclosed is an anti-tumor agent comprising a SNORA23 gene expression inhibitor. The SNORA23 expression inhibitor may be an oligonucleotide containing at least one nucleoside structure represented by formula (1) (wherein each of "Base" a...
|
|
WO/2018/134540A1 |
The invention relates to the use of the CD71 receptor as a target in the prognosis and/or treatment of endometriosis, and to a test for the prognosis or therapeutic monitoring of endometriosis, targeting this receptor.
|
|
WO/2018/133563A1 |
Disclosed are a Panax plant extract and a pharmaceutical composition and the use thereof. The mass ratio of Rk1 and Rg5 in the Panax plant extract is 1 : 1.0-1.5, and the content of Rg3, Rg5 and Rk1 in the extract is relatively high. The...
|
|
WO/2018/128956A1 |
Disclosed are systemic and intravaginal non-hormonal contraceptives comprising a spermicidal triterpenoid. The contraceptive may be in the form of a foam, cream or gel, or in unit form of a pill, vaginal contraceptive film (VCF), supposi...
|
|
WO/2018/129369A1 |
Described are methods for reversible occlusion of a body lumen by way of degradation as a result of exposure to one or more stimuli such as light. The methods include administering one or more substance(s) into a body lumen of a subject ...
|
|
WO/2018/121551A1 |
The present invention relates to an azabicyclo-substituted triazole derivative, a preparation method thereof, and an application of the same in medicine. In particular, the present invention relates to a novel azabicyclo-substituted tria...
|
|
WO/2018/123680A1 |
In order to provide a novel means for ameliorating mastitis or improving milk production, the present invention provides a mastitis ameliorating or treating agent or a milk production promoting agent that contains a biosurfactant.
|
|
WO/2018/123908A1 |
[Problem] An objective of the present invention is to provide a novel composition that can inhibit the activity of PDE5. [Solution] A composition for inhibiting phosphodiesterase-5 activity, the composition comprising a processed product...
|
|
WO/2018/114514A1 |
The invention relates to the use of by cyclically-substituted uracil derivatives, on their own or in combination with other active substances, for the treatment and/or prophylaxis of illnesses, in particular for the treatment and/or prop...
|
|
WO/2018/113694A1 |
The present invention relates to a condensed ring group azacyclobutyl triazole derivative, a preparation method therefor and use thereof in medicine. In particular, the present invention relates to a novel condensed ring group azacyclobu...
|
|
WO/2018/113272A1 |
The present invention relates to a pharmaceutical composition comprising an oxytocin analog, a preparation method therefor, and a use thereof. The pharmaceutical composition comprises an oxytocin analog, an excipient, and a divalent meta...
|
|
WO/2018/113273A1 |
A pharmaceutical composition comprising carbetocin, comprising (percent by weight): 0.5%-7% of carbetocin, 1%-10% of a water-soluble matrix material, 0.5%-5% of an amino acid anionic surfactant, 0.1%-5% of a humectant, and the balance of...
|
|
WO/2018/108879A1 |
The present invention relates to a composition for use in treating symptoms relating to premenstrual syndrome (PMS). The composition for use in treating dysphoria, depression and/or mood swings relating to PMS comprises as first active i...
|
|
WO/2018/106914A1 |
The subject matter of the present invention is pertinent to the field of oral delivery of pharmaceutically active agents. Embodiments of the instant invention disclose a liquid or semi-solid non-aqueous oral pharmaceutical fill compositi...
|
|
WO/2018/100214A1 |
Veterinary composition for manufacturing a semen enhancer, useful for artificial insemination in animals. The present invention refers to a composition for manufacturing a semen additive characterized in that it contains oxytocin, lecire...
|
|
WO/2018/102233A1 |
The invention provides compositions and methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its deriv...
|
|
WO/2018/100533A1 |
The invention relates to compositions for vaginal or, alternatively, oral administration and to the use of such compositions for stabilizing the vaginal, or, alternatively, the intestinal acidity and establishing favorable conditions for...
|
|
WO/2018/094955A1 |
Provided is a long non-coding RNA, PVT1, and the nucleotide sequence thereof is shown in SEQ ID NO: 1. Also provided are a pharmaceutical composition comprising PVT1, a primer for detecting PVT1 and a kit comprising the primer, an siRNA ...
|
|
WO/2018/093369A1 |
Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using topical application of alpha-1 adrenergic receptor agonists, muscarinic acetylcholine receptor agonists, nicotinic acetylcholine receptor ag...
|
|
WO/2018/086501A1 |
A novel ironing moxibustion apparatus combining moxibustion and ironing methods. Before and after use, the variation value of a grease parameter in a grease-containing Artemisia vulgaris product is less than 50% (0.5), wherein a grease c...
|
|
WO/2018/088240A1 |
Provided is a method for preparing a Leydig-like cell from a human pluripotent stem cell. Further provided is a human pluripotent stem cell-derived Leydig-like cell. It is possible to prepare a Leydig-like cell by overexpressing the NR5A...
|
|
WO/2018/086608A1 |
Provided are a crystalline form of a GnRH receptor antagonist and a preparation method therefor. Specifically, provided are a crystalline form I of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6-
methoxypyridazin-3-yl)-4,6-d...
|
|
WO/2018/083508A1 |
Oral compositions comprising as active ingredients a combination of fatty acids or esters thereof for use in a method for the treatment of repeated spontaneous abortions or repeated implantation failures after in vitro fertilization in s...
|
|
WO/2018/082687A1 |
Disclosed are a polymorphic form of a GnRH receptor antagonist and a preparation method therefor. In particular, disclosed are polymorphic forms A, B, C, and D of 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6-
methoxypyrida...
|
|
WO/2018/081138A1 |
Biodegradable contraceptive implants and methods of making and using thereof, are preferably formed of poly(ω-pentadecalactone-co-p-dioxanone) [poly(PDL-co-DO)], a family of polyester copolymers that degrade slowly in the presence of wa...
|
|
WO/2018/076074A1 |
A method to increase the penetration of active agents through mucosal membranes, the method comprising the step of: a) administering to a subject in need a composition comprising: i) one or more hydrotropes in a total amount of less than...
|
|
WO/2018/078336A1 |
Disclosed are acidic feminine intimate cleansing compositions having a pH in the range of from 3 to 5, which further necessarily comprises at least: as a primary antimicrobial active constituent, lactic acid, which may optionally be a su...
|
|
WO/2018/080353A1 |
The invention relates to the field of medicine and pharmaceutics, particularly to new pharmaceutical compositions for intranasal administration, comprising heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro or its pharmaceutically acceptable salin...
|
|
WO/2018/080349A1 |
The invention relates to peptide chemistry, pharmacology, and medicine, and specifically to a new group of peptides having the property of stimulating sexual and genital function and having increased storage stability. For this purpose, ...
|
|
WO/2018/073821A1 |
The present invention provides combined compositions and kits including Isosorbide mono-nitrate, DMI or Isosorbide dinitrate Moxisylyte, Hydralazine Arginine Norvaline, and their combinations, and a topical carrier. Methods for inducing ...
|
|
WO/2018/070971A1 |
The invention relates to a pharmaceutical composition in the form of an oromucosal spray for treating erectile dysfunction and pulmonary arterial hypertension, which is non-aqueous, has a Hammett acidity value of at least 4, and comprise...
|
|
WO/2018/068498A1 |
An oral dissolvable film of tadalafil and a preparation method therefor. The oral dissolvable film of tadalafil is prepared from tadalafil, a film-forming material, a plasticizer, an optionally existing corrective, an optionally existing...
|
|
WO/2018/066707A1 |
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...
|
|
WO/2018/065076A1 |
The present invention relates to a method for the management of dysmenorrhea involving administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-lik...
|
|
WO/2018/065900A1 |
The present invention relates to a Feed formulation and food supplement containing Goji berries (Lycium barbarum) or extracts thereof to increase female fertility.
|
|
WO/2018/064978A1 |
Uses of a bacteriostatic agent formula in preparing a composition for vaginal use. The bacteriostatic agent formula provides enhanced inhibitory effects with respect to Escherichia coli and/or Staphylococcus aureus and/or Candida. Also r...
|
